103 related articles for article (PubMed ID: 21143005)
1. Phospholipase A₂ activity in first episode schizophrenia: associations with symptom severity and outcome at week 12.
Smesny S; Kunstmann C; Kunstmann S; Willhardt I; Lasch J; Yotter RA; Proffitt TM; Kerr M; Marculev C; Milleit B; Milleit C; Nenadic I; Amminger P; McGorry PD; Sauer H; Berger GE
World J Biol Psychiatry; 2011 Dec; 12(8):598-607. PubMed ID: 21143005
[TBL] [Abstract][Full Text] [Related]
2. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
[TBL] [Abstract][Full Text] [Related]
3. Antipsychotic treatment in child and adolescent first-episode psychosis: a longitudinal naturalistic approach.
Castro-Fornieles J; Parellada M; Soutullo CA; Baeza I; Gonzalez-Pinto A; Graell M; Paya B; Moreno D; de la Serna E; Arango C
J Child Adolesc Psychopharmacol; 2008 Aug; 18(4):327-36. PubMed ID: 18759642
[TBL] [Abstract][Full Text] [Related]
4. White-matter microstructure in previously drug-naive patients with schizophrenia after 6 weeks of treatment.
Wang Q; Cheung C; Deng W; Li M; Huang C; Ma X; Wang Y; Jiang L; Sham PC; Collier DA; Gong Q; Chua SE; McAlonan GM; Li T
Psychol Med; 2013 Nov; 43(11):2301-9. PubMed ID: 23442742
[TBL] [Abstract][Full Text] [Related]
5. Cognition, functioning and quality of life in schizophrenia treatment: results of a one-year randomized controlled trial of olanzapine and quetiapine.
Voruganti LP; Awad AG; Parker G; Forrest C; Usmani Y; Fernando ML; Senthilal S
Schizophr Res; 2007 Nov; 96(1-3):146-55. PubMed ID: 17728106
[TBL] [Abstract][Full Text] [Related]
6. [Quality of life and social functioning in schizophrenic patients treated with olanzapine: 1 year follow-up naturalistic study].
Mayoral F; Montejo AL; Bousoño M; González-Torres MA; Olivares JM; Ros S; Sanjuán J; Escobar R; Lara N
Actas Esp Psiquiatr; 2006; 34(1):7-15. PubMed ID: 16525900
[TBL] [Abstract][Full Text] [Related]
7. A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLA trial.
Sacchetti E; Valsecchi P; Parrinello G;
Schizophr Res; 2008 Jan; 98(1-3):55-65. PubMed ID: 17933497
[TBL] [Abstract][Full Text] [Related]
8. Prolactin, subjective well-being and sexual dysfunction: an open label observational study comparing quetiapine with risperidone.
Westheide J; Cvetanovska G; Albrecht C; Bliesener N; Cooper-Mahkorn D; Creutz C; Hornung WP; Klingmüller D; Lemke MR; Maier W; Schubert M; Sträter B; Kühn KU
J Sex Med; 2008 Dec; 5(12):2816-26. PubMed ID: 18466271
[TBL] [Abstract][Full Text] [Related]
9. Predictors of response to second generation antipsychotics in drug naïve patients with schizophrenia: a 1 year follow-up study in Shanghai.
Zhang HX; Shen XL; Zhou H; Yang XM; Wang HF; Jiang KD
Psychiatry Res; 2014 Jan; 215(1):20-5. PubMed ID: 24230993
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
[TBL] [Abstract][Full Text] [Related]
11. Early use of clozapine for poorly responding first-episode psychosis.
Agid O; Remington G; Kapur S; Arenovich T; Zipursky RB
J Clin Psychopharmacol; 2007 Aug; 27(4):369-73. PubMed ID: 17632221
[TBL] [Abstract][Full Text] [Related]
12. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.
Keefe RS; Sweeney JA; Gu H; Hamer RM; Perkins DO; McEvoy JP; Lieberman JA
Am J Psychiatry; 2007 Jul; 164(7):1061-71. PubMed ID: 17606658
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.
Stroup TS; Lieberman JA; McEvoy JP; Swartz MS; Davis SM; Capuano GA; Rosenheck RA; Keefe RS; Miller AL; Belz I; Hsiao JK;
Am J Psychiatry; 2007 Mar; 164(3):415-27. PubMed ID: 17329466
[TBL] [Abstract][Full Text] [Related]
14. Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning.
Kinon BJ; Noordsy DL; Liu-Seifert H; Gulliver AH; Ascher-Svanum H; Kollack-Walker S
J Clin Psychopharmacol; 2006 Oct; 26(5):453-61. PubMed ID: 16974184
[TBL] [Abstract][Full Text] [Related]
15. Sensorimotor gating and habituation in antipsychotic-naive, first-episode schizophrenia patients before and after 6 months' treatment with quetiapine.
Aggernaes B; Glenthoj BY; Ebdrup BH; Rasmussen H; Lublin H; Oranje B
Int J Neuropsychopharmacol; 2010 Nov; 13(10):1383-95. PubMed ID: 20633319
[TBL] [Abstract][Full Text] [Related]
16. One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naive patients with a first-episode psychosis.
San L; Arranz B; Perez V; Safont G; Corripio I; Ramirez N; Dueñas R; Alvarez E
Psychiatry Res; 2012 Dec; 200(2-3):693-701. PubMed ID: 22954905
[TBL] [Abstract][Full Text] [Related]
17. An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis.
Agid O; Arenovich T; Sajeev G; Zipursky RB; Kapur S; Foussias G; Remington G
J Clin Psychiatry; 2011 Nov; 72(11):1439-44. PubMed ID: 21457676
[TBL] [Abstract][Full Text] [Related]
18. A comparative pilot study of second-generation antipsychotics in children and adolescents with schizophrenia-spectrum disorders.
Jensen JB; Kumra S; Leitten W; Oberstar J; Anjum A; White T; Wozniak J; Lee SS; Schulz SC
J Child Adolesc Psychopharmacol; 2008 Aug; 18(4):317-26. PubMed ID: 18759641
[TBL] [Abstract][Full Text] [Related]
19. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
Keefe RS; Bilder RM; Davis SM; Harvey PD; Palmer BW; Gold JM; Meltzer HY; Green MF; Capuano G; Stroup TS; McEvoy JP; Swartz MS; Rosenheck RA; Perkins DO; Davis CE; Hsiao JK; Lieberman JA; ;
Arch Gen Psychiatry; 2007 Jun; 64(6):633-47. PubMed ID: 17548746
[TBL] [Abstract][Full Text] [Related]
20. Progressive striatal and hippocampal volume loss in initially antipsychotic-naive, first-episode schizophrenia patients treated with quetiapine: relationship to dose and symptoms.
Ebdrup BH; Skimminge A; Rasmussen H; Aggernaes B; Oranje B; Lublin H; Baaré W; Glenthøj B
Int J Neuropsychopharmacol; 2011 Feb; 14(1):69-82. PubMed ID: 20701823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
